[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

CO6270385A2 - Bromhidrato de bupropion y aplicaciones terapeuticas - Google Patents

Bromhidrato de bupropion y aplicaciones terapeuticas

Info

Publication number
CO6270385A2
CO6270385A2 CO10051734A CO10051734A CO6270385A2 CO 6270385 A2 CO6270385 A2 CO 6270385A2 CO 10051734 A CO10051734 A CO 10051734A CO 10051734 A CO10051734 A CO 10051734A CO 6270385 A2 CO6270385 A2 CO 6270385A2
Authority
CO
Colombia
Prior art keywords
hci
modified release
dissolution medium
composition
ethanol
Prior art date
Application number
CO10051734A
Other languages
English (en)
Inventor
Graham Jackson
Werner Oberegger
Paul Maes
Mohammad Ashty Saleh
Original Assignee
Biovail Lab Int Srl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40521541&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO6270385(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biovail Lab Int Srl filed Critical Biovail Lab Int Srl
Publication of CO6270385A2 publication Critical patent/CO6270385A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Materials For Medical Uses (AREA)

Abstract

1.- Una composicion de bromhidrato de bupropion de liberacion modificada que comprende: un n·cleo que comprende una cantidad terapéuticamente eficaz de bromhidrato de bupropion; y un recubrimiento polimérico de liberacion controlada que comprende un polimero insoluble en agua y un polimero hidrosoluble; donde dicho recubrimiento rodea al menos parcialmente a dicho n·cleo; y donde dicha composicion libera bromhidrato de bupropion en un primer medio de disolucion conformado por HCI 0,1 N y 5%-40% v/v de etanol a una velocidad menor o igual a aproximadamente 1,1 veces la velocidad de liberacion de bromhidrato de bupropion a partir de una composicion farmacéutica de liberacion modificada idéntica en un segundo medio de disolucion conformado por HCI 0,1 N, medidas durante un periodo de tiempo de al menos 0 a 2 horas medidas empleando un aparato USP l a 75 rpm y a 37 0.5 °C.2.- La composicion de liberacion modificada de acuerdo con la reivindicacion 1, donde dicha composicion libera bromhidrato de bupropion en un primer medio de disolucion conformado por HCI 0,1 N y 5%-40% v/v de etanol a una velocidad que es menor o igual a la velocidad de liberacion de bromhidrato de bupropion de la composicion idéntica de liberacion modificada en un segundo medio de disolucion conformado por HCI 0,1 N.3.- La composicion de liberacion modificada de acuerdo con la reivindicacion 2, donde el primer medio de disolucion esta conformado por HCI 0,1 N y 5% v/v de etanol.4.- La composicion de liberacion modificada de acuerdo con la reivindicacion 2, donde el primer medio de disolucion esta conformado por HCI 0,1 N y 40% v/v de etanol.5.- La composicion de liberacion modificada de acuerdo con la reivindicacion 1, donde el periodo de tiempo es de 0 a 16 horas
CO10051734A 2007-10-31 2010-04-30 Bromhidrato de bupropion y aplicaciones terapeuticas CO6270385A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11/930,644 US7645802B2 (en) 2005-06-27 2007-10-31 Bupropion hydrobromide and therapeutic applications

Publications (1)

Publication Number Publication Date
CO6270385A2 true CO6270385A2 (es) 2011-04-20

Family

ID=40521541

Family Applications (1)

Application Number Title Priority Date Filing Date
CO10051734A CO6270385A2 (es) 2007-10-31 2010-04-30 Bromhidrato de bupropion y aplicaciones terapeuticas

Country Status (13)

Country Link
US (3) US7645802B2 (es)
EP (1) EP2214650A2 (es)
JP (1) JP2011500865A (es)
KR (1) KR20100077182A (es)
CN (1) CN101903016A (es)
AU (1) AU2008320915B2 (es)
CA (1) CA2699588A1 (es)
CO (1) CO6270385A2 (es)
MX (1) MX2010003872A (es)
NI (1) NI201000044A (es)
RU (1) RU2485942C2 (es)
WO (1) WO2009056550A2 (es)
ZA (1) ZA201003036B (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2578626C (en) 2005-06-27 2011-07-19 Biovail Laboratories International S.R.L. Modified-release formulations of a bupropion salt
US7645802B2 (en) * 2005-06-27 2010-01-12 Biovail Laboratories International Srl. Bupropion hydrobromide and therapeutic applications
US7671094B2 (en) * 2005-06-27 2010-03-02 Biovail Laboratories International S.R.L. Bupropion hydrobromide and therapeutic applications
PE20091156A1 (es) * 2007-12-17 2009-09-03 Astrazeneca Ab Sales de (3-{[[3-(6-amino-2-butoxi-8-oxo-7,8-dihidro-9h-purin-9-il)propil](3-morfolin-4-ilpropil)amino]metil}fenil)acetato de metilo
CA2934988A1 (en) * 2008-08-07 2010-02-11 Valeant International Bermuda Bupropion hydrobromide polymorphs
EP2323695B1 (en) * 2008-08-19 2018-12-05 Nektar Therapeutics Complexes of small-interfering nucleic acids
US8778398B2 (en) 2008-11-04 2014-07-15 Jazz Pharmaceuticals, Inc. Immediate release formulations and dosage forms of gamma-hydroxybutyrate
ITMI20090190A1 (it) * 2009-02-13 2010-08-14 Dipharma Francis Srl Forma cristallina di bupropione bromidrato
EP2549987A4 (en) * 2010-03-24 2015-01-21 Jazz Pharmaceuticals Inc CONTROLLED DOSAGE FOR HIGH-DOSE, WATER-SOLUBLE AND HYGROSCOPIC DRUGS
KR101873075B1 (ko) * 2010-08-18 2018-06-29 에보니크 룀 게엠베하 하나 이상의 알긴산 염을 포함하는 위 내성 제약 또는 건강기능식품 제제
EP2601973A1 (en) 2011-12-09 2013-06-12 Laboratoires SMB SA Dry powder formulation of azole derivative for inhalation
WO2015089150A1 (en) * 2013-12-10 2015-06-18 Forest Laboratories Holdings Limited Pharmaceutical formulations comprising vilazodone
SI3223797T1 (sl) * 2014-11-26 2020-06-30 Evonik Operations Gmbh Farmacevtski ali nutracevtski sestavek z odpornostjo na vpliv etanola
US10398662B1 (en) 2015-02-18 2019-09-03 Jazz Pharma Ireland Limited GHB formulation and method for its manufacture
WO2016140906A1 (en) * 2015-03-02 2016-09-09 Graphene 3D Lab Inc. Thermoplastic composites comprising water-soluble peo graft polymers useful for 3-dimensional additive manufacturing
US11602512B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11986451B1 (en) 2016-07-22 2024-05-21 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602513B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11504347B1 (en) 2016-07-22 2022-11-22 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
UY37341A (es) 2016-07-22 2017-11-30 Flamel Ireland Ltd Formulaciones de gamma-hidroxibutirato de liberación modificada con farmacocinética mejorada
US20180263936A1 (en) 2017-03-17 2018-09-20 Jazz Pharmaceuticals Ireland Limited Gamma-hydroxybutyrate compositions and their use for the treatment of disorders
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
MX2021005691A (es) 2018-11-19 2021-07-07 Jazz Pharmaceuticals Ireland Ltd Formulaciones de farmacos resistentes al alcohol.
WO2020178695A1 (en) 2019-03-01 2020-09-10 Flamel Ireland Limited Gamma-hydroxybutyrate compositions having improved pharmacokinetics in the fed state
CN113993522A (zh) 2019-04-17 2022-01-28 指南针探路者有限公司 用赛洛西宾治疗焦虑障碍、头痛病症和进食障碍的方法
US11583510B1 (en) 2022-02-07 2023-02-21 Flamel Ireland Limited Methods of administering gamma hydroxybutyrate formulations after a high-fat meal
US11779557B1 (en) 2022-02-07 2023-10-10 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6096341A (en) * 1998-10-30 2000-08-01 Pharma Pass Llc Delayed release tablet of bupropion hydrochloride
US6033686A (en) * 1998-10-30 2000-03-07 Pharma Pass Llc Controlled release tablet of bupropion hydrochloride
US6238697B1 (en) * 1998-12-21 2001-05-29 Pharmalogix, Inc. Methods and formulations for making bupropion hydrochloride tablets using direct compression
US8545880B2 (en) * 1999-02-26 2013-10-01 Andrx Pharmaceuticals, Llc Controlled release oral dosage form
US6337328B1 (en) * 1999-03-01 2002-01-08 Sepracor, Inc. Bupropion metabolites and methods of use
US6780871B2 (en) * 2001-01-29 2004-08-24 Albany Medical College Methods and compositions for treating addiction disorders
ME00391B (me) * 2003-08-08 2011-10-10 Biovail Laboratories Int Srl Tableta bupropion hidrohlorida sa modifikovanim otpuštanjem
CA2578626C (en) * 2005-06-27 2011-07-19 Biovail Laboratories International S.R.L. Modified-release formulations of a bupropion salt
US7645802B2 (en) 2005-06-27 2010-01-12 Biovail Laboratories International Srl. Bupropion hydrobromide and therapeutic applications
US7671094B2 (en) 2005-06-27 2010-03-02 Biovail Laboratories International S.R.L. Bupropion hydrobromide and therapeutic applications
WO2007078895A2 (en) * 2005-12-30 2007-07-12 Biovail Laboratories International S.R.L. Modified release formulations of tramadol and uses thereof
US20090004281A1 (en) * 2007-06-26 2009-01-01 Biovail Laboratories International S.R.L. Multiparticulate osmotic delivery system
CA2934988A1 (en) * 2008-08-07 2010-02-11 Valeant International Bermuda Bupropion hydrobromide polymorphs

Also Published As

Publication number Publication date
AU2008320915B2 (en) 2013-05-09
MX2010003872A (es) 2010-04-27
EP2214650A2 (en) 2010-08-11
JP2011500865A (ja) 2011-01-06
RU2485942C2 (ru) 2013-06-27
AU2008320915A1 (en) 2009-05-07
RU2010116863A (ru) 2011-12-10
WO2009056550A2 (en) 2009-05-07
ZA201003036B (en) 2011-07-27
US20130266650A1 (en) 2013-10-10
WO2009056550A3 (en) 2009-06-18
US20080274181A1 (en) 2008-11-06
NI201000044A (es) 2010-09-29
US20100255094A1 (en) 2010-10-07
KR20100077182A (ko) 2010-07-07
US7645802B2 (en) 2010-01-12
CN101903016A (zh) 2010-12-01
CA2699588A1 (en) 2009-05-07

Similar Documents

Publication Publication Date Title
CO6270385A2 (es) Bromhidrato de bupropion y aplicaciones terapeuticas
PE20191048A1 (es) Formas de dosificacion farmaceutica
BRPI0713481B8 (pt) composição farmacêutica de liberação controlada na forma de dosagem sólida, polímero linear, e, método para produzir um polímero linear
MA27523A1 (fr) Formulation retard a liberation controlee
ES2525530T3 (es) Sistemas de administración oral de liberación controlada
PE20001286A1 (es) FORMULACIONES FARMACEUTICAS DE LIBERACION CONTROLADA DE INHIBIDORES DE GMPc PDE-5
IL223488A (en) Injectable flow bar preparation containing buprenorphine
NZ604342A (en) Antipsychotic injectable depot composition
AR097045A2 (es) Sistema terapéutico transdérmico
DE502004005154D1 (de) Multipartikuläre arzneiform, enthaltend mucoadhaesiv formulierte peptid- oder protein-wirkstoffe, sowie ein verfahren zur herstellung der arzneiform
CO6270248A2 (es) Anclaje de combinacion para un dispositivo de ejercicio
PA8815901A1 (es) Sistema de administracion de drogas con efecto estabilizante
CR20110072A (es) Sistema de administración de drogas que contiene progestina
NZ586792A (en) Tamper resistant controlled release pharmaceutical tablets form having convex and concave surfaces
ES2422681T3 (es) Formulación de fármaco de moléculas pequeñas de liberación prolongada
EA201071054A1 (ru) Твердый препарат, растворяющийся во рту
IN266817B (es)
NO20072325L (no) Kombinasjonsterapi omfattende telmisartan og hydroklortiazid
CO6251360A2 (es) Bromhidrato de bupropion y aplicaciones terapeuticas
BRPI0817275A2 (pt) Combinação farmacêutica de alisquireno e valsartana
ES2569354T3 (es) Forma farmacéutica multiparticular, que contiene productos activos de ácido nucleico de formulación mucoadhesiva, así como un procedimiento para la obtención de la forma farmacéutica
UA99645C2 (ru) Гель, имеющий противовоспалительное и противоаллергическое действие
CL2007003643A1 (es) Composicion farmaceutica de azimilidina que comprende 0,5% a aproximadamente 2,5% (w/w) de agua; y uso para el tratamiento de arritmias cardiacas.
WO2009072334A1 (ja) 製剤用核粒子
MX2007008141A (es) Composicion farmaceutica de sustancias labiles en medio acido.

Legal Events

Date Code Title Description
FA Application withdrawn